HLS TherapeuticsTSX:HLS -1.12%62 FCF Margin % is 46.52% as of Mar. 2026, which is 106% above its 10-year median of 22.57. GuruFocus rates TSX:HLS with a GF Score™ of 62/100 and a GF Value™ of C$4.46 (Fairly Valued). The stock has 4 warning signs investors should review. Among 958 Drug Manufacturers companies, HLS Therapeutics ranks better than 96.56% on this metric.
The historical rank and industry rank for HLS Therapeutics's FCF Margin % or its related term are showing as below:
TSX:HLS'
s FCF Margin % Range Over the Past 10 Years
Min: -62.97 Med: 22.57 Max: 52.05
Current: 32.08
During the past 13 years, the highest FCF Margin % of HLS Therapeutics was 52.05%. The lowest was -62.97%. And the median was 22.57%.
TSX:HLS's FCF Margin % is ranked better than 96.56% of 958
companies
in the Drug Manufacturers industry
Industry Median: 2.51
vs TSX:HLS: 32.08
HLS Therapeutics FCF Margin % Related Terms
HLS Therapeutics FCF Margin % Historical Data
* Premium members only.
The historical data trend for HLS Therapeutics's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, HLS Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HLS Therapeutics FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, HLS Therapeutics's FCF Margin % distribution charts can be found below:
* The bar in red indicates where HLS Therapeutics's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HLS Therapeutics (TSX:HLS) has a FCF Margin % of 46.52% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on HLS Therapeutics and its competitors. This is 106% above median its historical median of 22.57. According to the industry distribution chart, HLS Therapeutics ranks #33 out of 958 companies in the Drug Manufacturers industry, placing it in the top 3.4%.
Is HLS Therapeutics' FCF Margin % too high?
HLS Therapeutics' current FCF Margin % of 46.52% is 106% above median its 10-year median of 22.57. The Drug Manufacturers industry median FCF Margin % is 2.51. HLS Therapeutics' value of 46.52% is 1753.4% above this industry median. Based on the distribution chart, HLS Therapeutics ranks #33 out of 958 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, HLS Therapeutics has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does HLS Therapeutics' FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, HLS Therapeutics ranks #33 out of 958 companies for FCF Margin %. This places HLS Therapeutics in the top 3% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 2.51. HLS Therapeutics' value of 46.52% is 1753.4% above this benchmark. While the company's 10-year median is 22.57 vs. the industry median of 2.51, HLS Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.51, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HLS Therapeutics's current FCF Margin % of 46.52% is 1753.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on HLS Therapeutics and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HLS Therapeutics's current FCF Margin % is 46.52%, which is 106% above median its own 10-year median of 22.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HLS Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, HLS Therapeutics (TSX:HLS) is currently considered Fairly Valued. The stock's GF Value™ is C$4.46, compared to a current price of C$4.42 — trading 0.9% below its estimated fair value. The current FCF Margin % is 46.52%, which is 106% above median its 10-year median of 22.57 and 1753.4% above the Drug Manufacturers industry median of 2.51. HLS Therapeutics' overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For HLS Therapeutics (TSX:HLS), the current FCF Margin % is 46.52% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HLS Therapeutics (TSX:HLS) Overvalued in 2026?
Based on GuruFocus' analysis, HLS Therapeutics stock appears to be undervalued.
The current stock price of C$4.42 is trading 0.9% below its estimated GF Value™ of C$4.46.
GuruFocus considers HLS Therapeutics to be Fairly Valued.
Key valuation signals for TSX:HLS:
FCF Margin %: 46.52% (106% above median its 10-year median of 22.57)
GF Value™: C$4.46 vs. price of C$4.42 (0.9% below fair value)
Industry Position: 1753.4% above the Drug Manufacturers median (#33 of 958)
No single metric tells the full story. See the TSX:HLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company's products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of world, with the majority of its revenue generated from Canada.
62GF Score
Get the complete analysis for TSX:HLS
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:HLS has been successfully added to your 
